Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00230516|
Recruitment Status : Completed
First Posted : October 3, 2005
Last Update Posted : January 4, 2013
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Nexium Drug: Prevacid||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects on Days 1 and 5 of Intravenous Treatment|
|Study Start Date :||September 2005|
|Actual Study Completion Date :||February 2006|
- The primary objective is to compare the pharmacodynamic efficacy in controlling intragastric pH of esomeprazole 40mg and lansoprazole 30mg on Day 5 of once daily IV administration to healthy volunteers.
- Secondary Outcomes will compare additional efficacy and safety parameters.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230516
|United States, California|
|Los Angeles, California, United States|
|United States, Oklahoma|
|Oklahoma City, Oklahoma, United States|
|Study Director:||Nexium Medical Science Director, MD||AstraZeneca|